Top

Published in:

01-12-2020 | Breast Cancer | Clinical trial

Comparison of resection margin status after single or double radiopaque marker insertion for tumor localization in breast cancer patients receiving neoadjuvant chemotherapy

Authors: Chihwan Cha, Janghee Lee, Dooreh Kim, Soeun Park, Soong June Bae, Na Lae Eun, Sung Gwe Ahn, Eun Ju Son, Joon Jeong

Published in: Breast Cancer Research and Treatment | Issue 3/2020

Abstract

Purpose

Insertion of radiopaque markers is helpful for tumor localization in patients receiving neoadjuvant chemotherapy (NAC) followed by breast-conserving surgery (BCS). The aim of this retrospective study was to investigate the pathologic margin status in patients with single or double marker insertion.

Methods

We reviewed the records of 130 patients with marker insertion prior to NAC followed by BCS from January 2016 to September 2019. Under ultrasonography guidance, single or double markers were inserted to localize a tumor in the breast. The incidence of additional resection after frozen biopsy and re-excision after permanent pathologic diagnosis was analyzed.

Results

In a total of 130 patients, 104 had a single marker in the center of the tumor and 26 had double markers at the periphery of the tumor before NAC. Among 69 patients with residual invasive tumors after NAC, there was no difference in the additional resection rate after frozen biopsy (single vs. double markers; 14.3% vs. 38.5%, P = .059) or the re-excision rate after final pathologic diagnosis (0% vs. 7.7%, P = .188). After propensity score matching for tumor size and subtypes, the two groups showed no differences in the additional resection rate after frozen biopsy (7.7% vs. 19.2%, P = .139) or the re-excision rate (0% vs. 3.8%, P = .308). After a median follow-up of 19 months (range 8–48 months), local recurrence-free survival did not differ between the two groups (log-rank P = .456).

Conclusions

Number of inserted markers for tumor localization did not affect the pathologic margin status after BCS.

Available only for authorised users

Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H et al (2007) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 18(12):1927–1934CrossRef

Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M et al (2012) Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 19(5):1508–1516CrossRef

Youn I, Choi SH, Kook SH, Choi YJ, Park CH, Park YL et al (2015) Ultrasonography-guided surgical clip placement for tumor localization in patients undergoing neoadjuvant chemotherapy for breast cancer. J Breast Cancer 18(1):44–49CrossRef

Schulz-Wendtland R, Dankerl P, Bani MR, Fasching PA, Heusinger K, Lux MP et al (2017) Evaluation of a marker clip system in sonographically guided core needle biopsy for breast cancer localization before and after neoadjuvant chemotherapy. Geburtshilfe Frauenheilkd 77(2):169–175CrossRef

Koo JH, Kim EK, Moon HJ, Yoon JH, Park VY, Kim MJ (2019) Comparison of breast tissue markers for tumor localization in breast cancer patients undergoing neoadjuvant chemotherapy. Ultrasonography 38(4):336–344CrossRef

Pinkney DM, Mychajlowycz M, Shah BA (2016) A prospective comparative study to evaluate the displacement of four commercially available breast biopsy markers. Br J Radiol 89(1065):20160149CrossRef

Oh JL, Nguyen G, Whitman GJ, Hunt KK, Yu TK, Woodward WA et al (2007) Placement of radiopaque clips for tumor localization in patients undergoing neoadjuvant chemotherapy and breast conservation therapy. Cancer 110(11):2420–2427CrossRef

Moran MS, Schnitt SJ, Giuliano AE et al (2014) Society of surgical oncology-American Society for radiation oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Ann Surg Oncol 21(3):704–716CrossRef

Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V et al (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25(28):4414–4422CrossRef

10.

Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G et al (2015) Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol 26(7):1280–1291CrossRef

11.

Sahoo S, Lester SC (2012) Pathology considerations in patients treated with neoadjuvant chemotherapy. Surg Pathol Clin 5(3):749–774CrossRef

12.

Pusztai L, Foldi J, Dhawan A, DiGiovanna MP, Mamounas EP (2019) Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers. Lancet Oncol 20(7):e390–e396CrossRef

13.

Cain H, Macpherson IR, Beresford M, Pinder SE, Pong J, Dixon JM (2017) Neoadjuvant therapy in early breast cancer: treatment considerations and common debates in practice. Clin Oncol (R Coll Radiol) 29(10):642–652CrossRef

14.

Aggarwal V, Agarwal G, Lal P, Krishnani N, Mishra A, Verma AK et al (2008) Feasibility study of safe breast conservation in large and locally advanced cancers with use of radiopaque markers to mark pre-neoadjuvant chemotherapy tumor margins. World J Surg 32(12):2562–2569CrossRef

15.

Espinosa-Bravo M, Sao Aviles A, Esgueva A, Cordoba O, Rodriguez J, Cortadellas T et al (2011) Breast conservative surgery after neoadjuvant chemotherapy in breast cancer patients: comparison of two tumor localization methods. Eur J Surg Oncol 37(12):1038–1043CrossRef

16.

Thomassin-Naggara I, Lalonde L, David J, Darai E, Uzan S, Trop I (2012) A plea for the biopsy marker: how, why and why not clipping after breast biopsy? Breast Cancer Res Treat 132(3):881–893CrossRef

17.

Ruland AM, Hagemann F, Reinisch M, Holtschmidt J, Kummel A, Dittmer-Grabowski C et al (2018) Using a New marker clip system in breast cancer: Tumark vision^® clip—feasibility testing in everyday clinical practice. Breast Care (Basel) 13(2):116–120CrossRef

18.

Masroor I, Zeeshan S, Afzal S, Sufian SN, Ali M, Khan S et al (2015) Outcome and cost effectiveness of ultrasonographically guided surgical clip placement for tumor localization in patients undergoing neo-adjuvant chemotherapy for breast cancer. Asian Pac J Cancer Prev 16(18):8339–8343CrossRef

19.

Volders JH, Haloua MH, Krekel NM, Negenborn VL, Barbe E, Sietses C et al (2016) Neoadjuvant chemotherapy in breast-conserving surgery—consequences on margin status and excision volumes: a nationwide pathology study. Eur J Surg Oncol 42(7):986–993CrossRef

20.

Volders JH, Negenborn VL, Spronk PE, Krekel NMA, Schoonmade LJ, Meijer S et al (2018) Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes. Breast Cancer Res Treat 168(1):1–12CrossRef

21.

Sahoo S, Lester SC (2009) Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting. Arch Pathol Lab Med 133(4):633–642PubMed

22.

Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED et al (2004) Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol 22(12):2303–2312CrossRef

23.

Wang S, Zhang Y, Yang X, Fan L, Qi X, Chen Q et al (2013) Shrink pattern of breast cancer after neoadjuvant chemotherapy and its correlation with clinical pathological factors. World J Surg Oncol 11(1):166CrossRef

Title: Comparison of resection margin status after single or double radiopaque marker insertion for tumor localization in breast cancer patients receiving neoadjuvant chemotherapy
Authors: Chihwan Cha
Janghee Lee
Dooreh Kim
Soeun Park
Soong June Bae
Na Lae Eun
Sung Gwe Ahn
Eun Ju Son
Joon Jeong
Publication date: 01-12-2020
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Cytostatic Therapy
Published in: Breast Cancer Research and Treatment / Issue 3/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05907-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2020

Clinical practice to address tamoxifen nonadherence

Atypical ductal hyperplasia bordering on DCIS on core biopsy is associated with higher risk of upgrade than conventional atypical ductal hyperplasia

Racial differences in genomic testing and receipt of endocrine therapy in early-stage breast cancer

Predicting adjuvant endocrine therapy initiation and adherence among older women with early-stage breast cancer

Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience

Acknowledgement of reviewers 2019

Keynote webinar | Spotlight on antibody–drug conjugates in cancer